Understanding the biology of angiogenesis: Review of the most important molecular mechanisms

Blood Cells, Molecules, and Diseases

Volumn 39, Issue 2, 2007, Pages 212-220

  Otrock, Zaher K ^a   Mahfouz, Rami A R ^a   Makarem, Jawad A ^a   Shamseddine, Ali I ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; CYTOKINE; FIBROBLAST GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; CELL PROLIFERATION; DEVELOPMENT; ENDOTHELIUM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REPRODUCTION; REVIEW; WOUND HEALING;

ANGIOGENIC PROTEINS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 34547221505     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2007.04.001     Document Type: Review

References (133)

1. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
2. Folkman J. In: DeVita V., Hellman S., and Rosenberg S.A. (Eds). Biologic Therapy of Cancer (1991), J.B. Lippincott Co., Philadelphia 743-753
3. Folkman J., and Shing Y. Angiogenesis. J. Biol. Chem. 267 (1992) 10931-10934
4. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 82 (1990) 4-6
5. Greenblatt M., and Shubi P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J. Natl. Cancer Inst. 41 (1968) 111-124
6. Ehrmann R.L., and Knoth M. Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. J. Natl. Cancer Inst. 41 (1968) 1329-1341
7. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6 (2000) 389-395
8. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
9. Papetti M., and Herman I.M. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol., Cell Physiol. 282 (2002) C947-C970
10. Presta M., Dell'Era P., Mitola S., et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16 (2005) 159-178
11. Rini B.I., and Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 23 (2005) 1028-1043
12. Tischer E., Mitchell R., Hartman T., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266 (1991) 11947-11954
13. Neufeld G., Cohen T., Gengrinovitch S., et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13 (1999) 9-22
14. Nishi M., Abe Y., Tomii Y., et al. Cell binding isoforms of vascular endothelial growth factor-A (VEGF189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma. Int. J. Oncol. 26 (2005) 1517-1524
15. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20 (2002) 4368-4380
16. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
17. Cross M.J., Dixelius J., Matsumoto T., et al. VEGF-receptor signal transduction. Trends Biochem. Sci. 28 (2003) 488-494
18. Hood J.D., Meininger C.J., Ziche M., et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 274 (1998) H1054-H1058
19. Storkebaum E., Lambrechts D., and Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 26 (2004) 943-954
20. Jakeman L.B., Armanini M., Phillips H.S., et al. Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 133 (1993) 848-859
21. Shweiki D., Itin A., Neufeld G., et al. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J. Clin. Invest. 91 (1993) 2235-2243
22. Carmeliet P., Ferreira V., Breier G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
23. Brown L.F., Yeo K.T., Berse B., et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 176 (1992) 1359-1375
24. Silins G., Grimmond S., Egerton M., et al. Analysis of the promoter region of the human VEGF-related factor gene. Biochem. Biophys. Res. Commun. 230 (1997) 413-418
25. Nash A.D., Baca M., Wright C., et al. The biology of vascular endothelial growth factor-B (VEGF-B). Pulm. Pharmacol. Ther. 19 (2006) 61-69
26. Mould A.W., Tonks I.D., Cahill M.M., et al. Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum. 48 (2003) 2660-2669
27. Silvestre J.S., Tamarat R., Ebrahimian T.G., et al. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ. Res. 93 (2003) 114-123
28. Robinson C.J., and Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114 (2001) 853-865
29. Achen M.G., Jeltsch M., Kukk E., et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 548-553
30. Lee J., Gray A., Yuan J., et al. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1988-1992
31. Cao Y., Linden P., Farnebo J., et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14389-14394
32. Pepper M.S., Mandriota S.J., Jeltsch M., et al. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J. Cell. Physiol. 177 (1998) 439-452
33. Marconcini L., Marchio S., Morbidelli L., et al. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 9671-9676
34. Jeltsch M., Kaipainen A., Joukov V., et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276 (1997) 1423-1425
35. Lyttle D.J., Fraser K.M., Fleming S.B., et al. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J. Virol. 68 (1994) 84-92
36. Ogawa S., Oku A., Sawano A., et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 273 (1998) 31273-31282
37. Meyer M., Clauss M., Lepple-Wienhues A., et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18 (1999) 363-374
38. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9 (2003) 653-660
39. Yancopoulos G.D., Klagsbrun M., and Folkman J. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 93 (1998) 661-664
40. Korhonen J., Polvi A., Partanen J., et al. The mouse tie receptor tyrosine kinase gene: expression during embryonic angiogenesis. Oncogene. 9 (1994) 395-403
41. Dumont D.J., Gradwohl G., Fong G.H., et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 8 (1994) 1897-1909
42. Sato Y., and Rifkin D.B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J. Cell Biol. 109 (1989) 309-315
43. Puri M.C., Rossant J., Alitalo K., et al. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 14 (1995) 5884-5891
44. Dumont D.J., Yamaguchi T.P., Conlon R.A., et al. tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7 (1992) 1471-1480
45. Davis S., Aldrich T.H., Jones P.F., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87 (1996) 1161-1169
46. Koblizek T.I., Weiss C., Yancopoulos G.D., et al. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr. Biol. 8 (1998) 529-532
47. Suri C., McClain J., Thurston G., et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 282 (1998) 468-471
48. Chen J.X., Zeng H., Lawrence M.L., et al. Angiopoietin-1-induced angiogenesis is modulated by endothelial NADPH oxidase. Am. J. Physiol, Heart Circ. Physiol. 291 (2006) H1563-H1572
49. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 (1997) 55-60
50. Thomas K.A. Fibroblast growth factors. FASEB J. 1 (1987) 434-440
51. Gospodarowicz D., Abraham J.A., and Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 7311-7315
52. Terranova V.P., DiFlorio R., Lyall R.M., et al. Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J. Cell Biol. 101 (1985) 2330-2334
53. Millauer B., Wizigmann-Voos S., Schnurch H., et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72 (1993) 835-846
54. Folkman J., Langer R., Linhardt R.J., et al. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221 (1983) 719-725
55. Lobb R.R., Alderman E.M., and Fett J.W. Induction of angiogenesis by bovine brain derived class 1 heparin-binding growth factor. Biochemistry 24 (1985) 4969-4973
56. Cross M.J., and Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22 (2001) 201-207
57. Presta M., Tiberio L., Rusnati M., et al. Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. Cell Regul. 2 (1991) 719-726
58. Liotta L.A., Steeg P.S., and Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64 (1991) 327-336
59. Hiraoka N., Allen E., Apel I.J., et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95 (1998) 365-377
60. Mignatti P., and Rifkin D.B. Nonenzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. Adv. Cancer Res. 78 (2000) 103-157
61. Heldin C.H., and Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79 (1999) 1283-1316
62. Glade Bender J., Cooney E.M., Kandel J.J., et al. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist. Updat. 7 (2004) 289-300
63. Bar R.S., Boes M., Booth B.A., et al. The effects of platelet-derived growth factor in cultured microvessel endothelial cells. Endocrinology 124 (1989) 1841-1848
64. Battegay E.J., Rupp J., Iruela-Arispe L., et al. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J. Cell Biol. 125 (1994) 917-928
65. Nicosia R.F., Nicosia S.V., and Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am. J. Pathol. 145 (1994) 1023-1029
66. Edelberg J.M., Aird W.C., Wu W., et al. PDGF mediates cardiac microvascular communication. J. Clin. Invest. 102 (1998) 837-843
67. Risau W., Drexler H., Mironov V., et al. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7 (1992) 261-266
68. Oikawa T., Onozawa C., Sakaguchi M., et al. Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivo. Biol. Pharm. Bull. 17 (1994) 1686-1688
69. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev. 15 (2004) 215-228
70. Lindahl P., Johansson B.R., Leveen P., et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277 (1997) 242-245
71. Hellstrom M., Gerhardt H., Kalen M., et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol. 153 (2001) 543-553
72. Abramsson A., Lindblom P., and Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. 112 (2003) 1142-1151
73. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev., Cancer. 3 (2003) 401-410
74. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cells 6 (2004) 553-563
75. Massague J. The transforming growth factor-beta family. Annu. Rev. Cell Biol. 6 (1990) 597-641
76. van den Driesche S., Mummery C.L., and Westermann C.J. Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. Cardiovasc. Res. 58 (2003) 20-31
77. Srinivasan S., Hanes M.A., Dickens T., et al. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum. Mol. Genet. 12 (2003) 473-482
78. Goumans M.J., Lebrin F., and Valdimarsdottir G. Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc. Med. 13 (2003) 301-307
79. Waite K.A., and Eng C. From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. Nat. Rev., Genet. 4 (2003) 763-773
80. Ota T., Fujii M., Sugizaki T., et al. Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J. Cell. Physiol. 193 (2002) 299-318
81. Tuxhorn J.A., McAlhany S.J., Yang F., et al. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res. 62 (2002) 6021-6025
82. Duff S.E., Li C., Renehan A., et al. Immunodetection and molecular forms of plasma vascular endothelial growth factor-C. Int. J. Oncol. 22 (2003) 339-343
83. Fett J.W., Strydom D.J., Lobb R.R., et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 24 (1985) 5480-5486
84. Hockel M., Jung W., Vaupel P., et al. Purified monocyte-derived angiogenic substance (angiotropin) induces controlled angiogenesis associated with regulated tissue proliferation in rabbit skin. J. Clin. Invest. 82 (1988) 1075-1090
85. Hodivala-Dilke K.M., McHugh K.P., Tsakiris D.A., et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 103 (1999) 229-238
86. Brooks P.C., Stromblad S., Sanders L.C., et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85 (1996) 683-693
87. Wang H.U., Chen Z.F., and Anderson D.J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93 (1998) 741-753
88. Esser S., Lampugnani M.G., Corada M., et al. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J. Cell Sci. 111 (1998) 1853-1865
89. Kevil C.G., Payne D.K., Mire E., et al. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J. Biol. Chem. 273 (1998) 15099-15103
90. Caveda L., Martin-Padura I., Navarro P., et al. Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5/VE-cadherin). J. Clin. Invest. 98 (1996) 886-893
91. Carmeliet P., Lampugnani M.G., Moons L., et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98 (1999) 147-157
92. Pepper M.S. Extracellular proteolysis and angiogenesis. Thromb. Haemost. 86 (2001) 346-355
93. Carmeliet P., and Collen D. Transgenic mouse models in angiogenesis and cardiovascular disease. J. Pathol. 190 (2000) 387-405
94. Chorostowska-Wynimko J., Swiercz R., Skrzypczak-Jankun E., et al. Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells. Oncol. Rep. 12 (2004) 1155-1162
95. Kroon M.E., Koolwijk P., van der Vecht B., et al. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix. Blood 96 (2000) 2775-2783
96. Uchiyama T., Kurabayashi M., Ohyama Y., et al. Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1155-1161
97. Bajou K., Noel A., Gerard R.D., et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4 (1998) 923-928
98. Heymans S., Luttun A., Nuyens D., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. 5 (1999) 1135-1142
99. Genis L., Galvez B.G., Gonzalo P., et al. MT1-MMP: universal or particular player in angiogenesis?. Cancer Metastasis Rev. 25 (2006) 77-86
100. Bergers G., Brekken R., McMahon G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2 (2000) 737-744
101. Plaisier M., Kapiteijn K., Koolwijk P., et al. Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: role of MT3-MMP. J. Clin. Endocrinol. Metab. 89 (2004) 5828-5836
102. Kraling B.M., Wiederschain D.G., Boehm T., et al. The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. J. Cell Sci. 112 (1999) 1599-1609
103. Zhu W.H., Guo X., Villaschi S., et al. Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Lab. Invest. 80 (2000) 545-555
104. Holmbeck K., Bianco P., Caterina J., et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99 (1999) 81-92
105. Zhou Z., Apte S.S., Soininen R., et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4052-4057
106. Chun T.H., Sabeh F., Ota I., et al. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J. Cell Biol. 167 (2004) 757-767
107. Oblander S.A., Zhou Z., Galvez B.G., et al. Distinctive functions of membrane type 1 matrix-metalloprotease (MT1-MMP or MMP-14) in lung and submandibular gland development are independent of its role in pro-MMP-2 activation. Dev. Biol. 277 (2005) 255-269
108. Galvez B.G., Matias-Roman S., Albar J.P., et al. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J. Biol. Chem. 276 (2001) 37491-37500
109. Galvez B.G., Matias-Roman S., Yanez-Mo M., et al. ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J. Cell Biol. 159 (2002) 509-521
110. Langlois S., Gingras D., and Beliveau R. Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood 103 (2004) 3020-3028
111. Robinet A., Fahem A., Cauchard J.H., et al. Elastin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation of MT1-MMP. J. Cell Sci. 118 (2005) 343-356
112. Semenza G.L., and Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12 (1992) 5447-5454
113. Wang G.L., Jiang B.H., Rue E.A., et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5510-5514
114. Goldberg M.A., and Schneider T.J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem. 269 (1994) 4355-4359
115. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16 (1996) 4604-4613
116. Melillo G., Musso T., Sica A., et al. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 182 (1995) 1683-1693
117. Currie M.J., Gunningham S.P., Turner K., et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J. Pathol. 198 (2002) 502-510
118. Mandriota S.J., Pyke C., Di Sanza C., et al. Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. Am. J. Pathol. 156 (2000) 2077-2089
119. Graham C.H., Fitzpatrick T.E., and McCrae K.R. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood 91 (1998) 3300-3307
120. Phelan M.W., Forman L.W., Perrine S.P., et al. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J. Lab. Clin. Med. 132 (1998) 519-529
121. Negus R.P., Turner L., Burke F., et al. Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors. J. Leukoc. Biol. 63 (1998) 758-765
122. Iyer N.V., Kotch L.E., Agani F., et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12 (1998) 149-162
123. Carmeliet P., Dor Y., Herbert J.M., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
124. Ryan H.E., Lo J., and Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17 (1998) 3005-3015
125. Liu Y., Cox S.R., Morita T., et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ. Res. 77 (1995) 638-643
126. Levy N.S., Chung S., Furneaux H., et al. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273 (1998) 6417-6423
127. Stein I., Itin A., Einat P., et al. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol. Cell Biol. 18 (1998) 3112-3119
128. Gerber H.P., Condorelli F., Park J., et al. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. 272 (1997) 23659-23667
129. Waltenberger J., Mayr U., Pentz S., et al. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 94 (1996) 1647-1654
130. Barleon B., Siemeister G., Martiny-Baron G., et al. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res. 57 (1997) 5421-5425
131. Tomita S., Ueno M., Sakamoto M., et al. Defective brain development in mice lacking the Hif-1alpha gene in neural cells. Mol. Cell. Biol. 23 (2003) 6739-6749
132. Manalo D.J., Rowan A., Lavoie T., et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105 (2005) 659-669
133. Tang N., Wang L., Esko J., et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cells 6 (2004) 485-495